Stockscreener 앱 받기
0.89
0.45%
-0.004
전일 마감가:
$0.894
열려 있는:
$0.88
하루 거래량:
48,330
Relative Volume:
0.51
시가총액:
$6.22M
수익:
-
순이익/손실:
$-14.29M
주가수익비율:
-0.2231
EPS:
-3.99
순현금흐름:
$-12.27M
1주 성능:
-5.84%
1개월 성능:
-2.31%
6개월 성능:
-46.39%
1년 성능:
-76.23%
1일 변동 폭
$0.88
$0.946
1주일 범위
$0.88
$0.99
52주 변동 폭
$0.84
$4.65
Aprea Therapeutics Inc Stock (APRE) Company Profile
명칭
Aprea Therapeutics Inc
전화
215-948-4119
주소
3805 OLD EASTON ROAD, DOYLESTOWN, MA
APRE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.89 | 6.25M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-06-22 | 개시 | H.C. Wainwright | Neutral |
| 2020-04-21 | 개시 | Robert W. Baird | Outperform |
| 2019-10-28 | 개시 | JP Morgan | Neutral |
| 2019-10-28 | 개시 | Morgan Stanley | Equal-Weight |
| 2019-10-28 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스
Is Aprea Therapeutics Inc stock a buy or sellJuly 2025 Volume & High Accuracy Investment Entry Signals - baoquankhu1.vn
Levels Update: Is Aprea Therapeutics Inc affected by consumer sentimentEarnings Overview Report & Growth Focused Stock Reports - baoquankhu1.vn
Aprea Therapeutics (NASDAQ:APRE) Cut to “Strong Sell” at Zacks Research - Defense World
Short Covering: Is Aprea Therapeutics Inc backed by strong institutional buyingQuarterly Investment Review & Safe Capital Growth Stock Tips - baoquankhu1.vn
New Strong Sell Stocks for Jan. 14 - sharewise.com
Is Aprea Therapeutics Inc affected by consumer sentimentJuly 2025 Earnings & Short-Term Swing Trade Alerts - baoquankhu1.vn
MSN Money - MSN
Aprea Therapeutics, Inc. Updates Corporate Presentation - TradingView — Track All Markets
Why Aprea Therapeutics Inc. stock is a value investor pickEarnings Risk Report & Weekly Hot Stock Watchlists - Улправда
Why retail investors favor Aprea Therapeutics Inc. stockMarket Weekly Review & Weekly Chart Analysis and Guides - Улправда
Why Aprea Therapeutics Inc. stock is considered a top pickJuly 2025 Analyst Calls & Weekly High Conviction Ideas - Улправда
Will Aprea Therapeutics Inc. stock outperform growth indexesInsider Selling & Weekly Setup with High ROI Potential - Улправда
Can Aprea Therapeutics Inc. stock reach $100 price targetM&A Rumor & High Accuracy Trade Signal Alerts - Улправда
Will Aprea Therapeutics Inc. stock reach all time highs in 2025Sell Signal & Technical Confirmation Alerts - Улправда
Dow Theory LettersAprea Therapeutics, Inc.Common Stock (Nasdaq:APRE) Price Chart - FinancialContent
Will Aprea Therapeutics Inc. stock deliver consistent dividendsJuly 2025 Rallies & Low Risk Growth Stock Ideas - Улправда
Why retail investors pile into Aprea Therapeutics Inc. stockJuly 2025 Institutional & High Accuracy Trade Signal Alerts - Улправда
Aprea Therapeutics, Inc.Common Stock (NQ: APRE - FinancialContent
Aprea Therapeutics files to sell 5.5M shares of common stock for holders - MSN
Aprea signals 2026 inflection as cancer trials advance and cash extends - MSN
Market Recap: Will Aprea Therapeutics Inc stock reach all time highs in 2025 - moha.gov.vn
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 41.3% in December - Defense World
Aprea Therapeutics (NASDAQ:APRE) vs. Affymax (OTCMKTS:AFFY) Financial Survey - Defense World
Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer - Quantisnow
Maxim Group Reaffirms Their Buy Rating on Aprea Therapeutics (APRE) - The Globe and Mail
Aprea Signals 2026 Inflection as Cancer Trials Advance and Cash Extends - MyChesCo
Can Aprea Therapeutics Inc. stock weather global recessionEnergy Sector Updates & Small Budget Capital Investment - bollywoodhelpline.com
Aprea Therapeutics (APRE) Stock Analysis Report | Financials & Insights - Benzinga
Will Aprea Therapeutics Inc. stock benefit from automationTrade Performance Summary & Weekly Return Optimization Alerts - Улправда
Why Aprea Therapeutics Inc. stock could rally in 20252025 Big Picture & Low Drawdown Investment Ideas - Улправда
Aprea Therapeutics (NASDAQ:APRE) Given New $5.00 Price Target at HC Wainwright - Defense World
Aprea Therapeutics reports progress in cancer drug development By Investing.com - Investing.com South Africa
HC Wainwright & Co. Maintains Aprea Therapeutics (APRE) Buy Recommendation - Nasdaq
APRE Analyst Forecasts - Quiver Quantitative
Aprea Therapeutics (APRE): HC Wainwright Maintains 'Buy' Rating, Lowers Price Target | APRE Stock News - GuruFocus
Aprea Therapeutics CEO issues letter to shareholders highlighting outlook for 2026 - marketscreener.com
Aprea Therapeutics reports progress in cancer drug development - Investing.com
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026 - The Manila Times
Aprea Therapeutics Highlights Clinical Progress and Strategic Plans in Shareholder Update Letter - Quiver Quantitative
Aprea Therapeutics Earnings Notes - Trefis
Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors - MSN
Insider Buying: John Hamill Acquires Additional Shares of Aprea Therapeutics Inc (APRE) - GuruFocus
Hamill, Aprea Therapeutics CFO, buys $5,825 in stock By Investing.com - Investing.com South Africa
Aprea therapeutics director Duey Marc buys $25,000 in shares By Investing.com - Investing.com Canada
Hamill, Sr. VP at Aprea Therapeutics, buys $5,825 in stock - Investing.com India
Hamill, Sr. VP at Aprea Therapeutics, buys $5,825 in stock By Investing.com - Investing.com South Africa
Hamill, Aprea Therapeutics CFO, buys $5,825 in stock - Investing.com
Aprea Therapeutics Inc (APRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aprea Therapeutics Inc 주식 (APRE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Dec 10 '25 |
Buy |
1.17 |
5,000 |
5,825 |
27,733 |
| Gilad Oren | President/CEO |
Apr 03 '25 |
Buy |
1.84 |
5,500 |
10,110 |
345,620 |
4.73%
0.92%
자본화:
|
볼륨(24시간):